Cardiac sarcoidosis: A review on the work-up and management

• Authors: Boris Solun , Dana Marcoviciu , Yulia Belnik , Tamar Azran , Dror Dicker , Yosef Perek , Orly Goitein
• Languages of publication: EN

Abstracts

EN

Sarcoidosis is a multisystem granulomatous disease of unknown etiology and with variable presentation. Skin, lymph nodes, lungs, eyes and the central nervous system are mostly involved. Cardiac sarcoidosis (CS) is a rare condition with clinical manifestations in about 5% of patients. Since it increases the risk of acute cardiac failure, ventricular arrhythmia, conduction disturbances and even sudden death, it aggravates markedly the prognosis. The early diagnosis of CS is difficult, requiring the use of diagnostic tools such as electrocardiographic monitoring, two-dimensional echocardiography, radionuclide scan, cardiac magnetic resonance imaging, positron emission tomography and endomyocardial biopsy. Once the diagnosis of CS is established, there is a need for early corticosteroids treatment, with or without immunosuppressive therapy, to prevent deterioration of cardiac function. In patients with refractory ventricular tachyarrhythmia, markedly reduced left ventricular ejection fraction and high risk of sudden death, prophylactic insertion of a pacemaker or implantable defibrillator is recommended. We had the opportunity to treat a patient with CS and to review the currently accepted diagnostic and treatment approach.

Keywords

EN

Cardiac sarcoidosis; Conduction disturbances; Corticosteroids

• Publisher: De Gruyter Open
• Journal: Open Medicine
• Year: 2013
• Volume: 8
• Issue: 1
• Pages: 107-116

Dates

published

1 - 2 - 2013

online

8 - 12 - 2012

Contributors

author

Boris Solun

• Department of Internal Medicine D, Hasharon Hospital, affiliated to the Sackler School of Medicine, Tel-Aviv University Petah Tikva, 7 Keren Kayemet St., Tel-Aviv, 49100, Israel

author

Dana Marcoviciu

• Department of Internal Medicine D, Hasharon Hospital, affiliated to the Sackler School of Medicine, Tel-Aviv University Petah Tikva, 7 Keren Kayemet St., Tel-Aviv, 49100, Israel

author

Yulia Belnik

• Department of Internal Medicine D, Hasharon Hospital, affiliated to the Sackler School of Medicine, Tel-Aviv University Petah Tikva, 7 Keren Kayemet St., Tel-Aviv, 49100, Israel

author

Tamar Azran

• Department of Internal Medicine D, Hasharon Hospital, affiliated to the Sackler School of Medicine, Tel-Aviv University Petah Tikva, 7 Keren Kayemet St., Tel-Aviv, 49100, Israel

author

Dror Dicker

• Department of Internal Medicine D, Hasharon Hospital, affiliated to the Sackler School of Medicine, Tel-Aviv University Petah Tikva, 7 Keren Kayemet St., Tel-Aviv, 49100, Israel

author

Yosef Perek

• Department of cardiology, Rabin Medical Center, Hasharon Hospital affiliated to the Sackler School of Medicine, Tel-Aviv University Petah Tikva, 7 Keren Kayemet St., Tel-Aviv, 49100, Israel

author

Orly Goitein

• Diagnostic Imaging, Sheba, Tel Hashomer, Israel

References

• [1] Iannuzzi M.C., Rybicki B.A., Teirstein A.S. Sarcoidosis., N. Engl. J. Med., 2007, 357, 2153–2165 http://dx.doi.org/10.1056/NEJMra071714[Crossref]
• [2] Dorfman T., Canales J., Farukhi I., McGuire D.K., Sarcoidosis masquerading as an acute coronary syndrome. Cardiol. Rev., 2005, 13, 256–259 http://dx.doi.org/10.1097/01.crd.0000153246.79653.4b[Crossref]
• [3] Pierre-Louis B., Prasad A., Frishman W.H., Cardiac manifestations of sarcoidosis and therapeutic options. Cardiol. Rev., 2009, 17, 153–158. http://dx.doi.org/10.1097/CRD.0b013e3181a1f763[Crossref]
• [4] Sun B.J., Lee P.H., Choi H.O., Ahn J.M, Seo J.S, Kim D.H., et al., Prevalence of echocardiographic features suggesting cardiac sarcoidosis in patients with pacemaker or implantable cardiac defibrillator. Korean Circ. J., 2011, 41, 313–320 http://dx.doi.org/10.4070/kcj.2011.41.6.313[Crossref][WoS]
• [5] Sohn I.S., Cardiac Sarcoidosis: Oldies but not goodies. Korean Circ J., 2011, 41, 296–298 http://dx.doi.org/10.4070/kcj.2011.41.6.296[WoS][Crossref]
• [6] Patel M.R., Cawley P.J., Heitner J.F., Klem I, Parker M.A, Jaroudi W.A., et al., Detection of myocardial damage in patients with sarcoidosis. Circulation, 2009, 120, 1969–1977 http://dx.doi.org/10.1161/CIRCULATIONAHA.109.851352[Crossref]
• [7] Nunes H., Freynet O., Naggara N., Soussan M, Weinman P, Diebold B., et al., Cardiac sarcoidosis. Semin. Respir. Crit. Care Med., 2010, 31, 428–441 http://dx.doi.org/10.1055/s-0030-1262211[WoS][Crossref]
• [8] Hiraga H., Yuwai K., Hiroe M., Guideline for diagnosis of cardiac sarcoidosis: study report on diffuse pulmonary disease from the Japanese Ministry of Health and Welfare. 1993, 23–24
• [9] Mitropoulos F.A., Floudas C.S., Kanakis M.A., Vaiopoulos G.A., Cardiac sarcoidosis. Thorac. Cardiovasc. Surg., 2009, 57, 187–190 [Crossref][WoS]
• [10] Hamzeh N.Y., Wamboldt F.S., Weinberger H.D., Management of cardiac sarcoidosis in the United States: a delphi study. Chest., 2012, 141, 154–162 http://dx.doi.org/10.1378/chest.11-0263[Crossref][WoS]
• [11] Dubrey S.W., Falk R.H., Diagnosis and management of cardiac sarcoidosis. Prog. Cardiovasc. Dis., 2010, 52, 336–346 http://dx.doi.org/10.1016/j.pcad.2009.11.010[Crossref]
• [12] Soejima K., Yada H., The work-up and management of patients with apparent or subclinical cardiac sarcoidosis: with emphasis on the associated heart rhythm abnormalities. J Cardiovasc Electrophysiol., 2009, 5, 578–583 http://dx.doi.org/10.1111/j.1540-8167.2008.01417.x[Crossref]
• [13] Divakara Menon S.M., Chemello D., Morillo C.A., Sarcoidosis: yet another masquerader the cardiologist / electrophysiologist has to fight with. Indian Pacing Electrophysiol. J., 2010, 10, 479–485
• [14] Homsi M., Alsayed L., Safadi B., Mahenthiran J., Das M.K., Fragmented QRS complexes on 12-lead ECG: a marker of cardiac sarcoidosis as detected by gadolinium cardiac magnetic resonance imaging. Ann. Noninvasive Electrocardiol., 2009, 14, 319–326 http://dx.doi.org/10.1111/j.1542-474X.2009.00320.x[Crossref][WoS]
• [15] Suzuki T., Kanda T., Kubota S., Imai S., Murata K., Holter monitoring as a noninvasive indicator of cardiac involvement in sarcoidosis. Chest, 1994, 106, 1021–1024 http://dx.doi.org/10.1378/chest.106.4.1021[Crossref]
• [16] Petrović M., Vujisić-Tesić B., Boricić M., Spectrum of echocardiographic findings in patients with systemic sarcoidosis. Med. Pregl., 2005; 58Suppl 1:35–38
• [17] Hyodo E., Hozumi T., Takemoto Y., Watanabe H., Muro T., Yamagishi H., et al., Early detection of cardiac involvement in patients with sarcoidosis by a non-invasive method with ultrasonic tissue characterisation. Heart, 2004, 90, 1275–1280 http://dx.doi.org/10.1136/hrt.2003.027763[Crossref]
• [18] Tellier P., Paycha F., Antony I., Nitenberg A., Valeyre D., Foult J.M., et al., Reversibility by dipyridamole of thallium 201 myocardial scan defects in patients with sarcoidosis. Am. J. Med., 1988, 85, 189–193 http://dx.doi.org/10.1016/S0002-9343(88)80340-1[Crossref]
• [19] Nery P.B., Leung E., Birnie D.H., Arrhythmias in cardiac sarcoidosis: diagnosis and treatment. Curr. Opin. Cardiol., 2012, 27, 181–189 http://dx.doi.org/10.1097/HCO.0b013e32834e4c7c[Crossref]
• [20] Futamatsu H., Suzuki J., Adachi S., Okada H., Otomo K., Ohara T., et al., Utility of gallium-67 scintigraphy for evaluation of cardiac sarcoidosis with ventricular tachycardia. Int. J. Cardiovasc. Imaging, 2006, 22, 443–448 http://dx.doi.org/10.1007/s10554-005-9043-x
• [21] Okayama K., Kurata C., Tawarahara K., Wakabayashi Y., Chida K., Sato A., Diagnostic and prognostic value of myocardial scintigraphy with thallium-201 and gallium-67 in cardiac sarcoidosis. Chest, 1995, 107, 330–334 http://dx.doi.org/10.1378/chest.107.2.330
• [22] Sekhri V., Sanal S., Delorenzo L.J., Aronow W.S., Maguire G.P., Cardiac sarcoidosis: a comprehensive review. Arch. Med. Sci., 2011, 7, 546–554 http://dx.doi.org/10.5114/aoms.2011.24118[Crossref][WoS]
• [23] Ohira H., Tsujino I., Yoshinaga K., 18F-Fluoro-2-deoxyglucose positron emission tomography in cardiac sarcoidosis. Eur. J. Nucl. Med. Mol. Imaging., 2011, 38, 1773–1783 http://dx.doi.org/10.1007/s00259-011-1832-y[Crossref]
• [24] Youssef G., Leung E., Mylonas I., Nery P., Williams K., Wisenberg G., et al., The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: A Systematic review and metaanalysis including the Ontario experience. J. Nucl. Med., 2012, 53, 241–248 http://dx.doi.org/10.2967/jnumed.111.090662[WoS][Crossref]
• [25] Mañá J., Gámez C., Molecular imaging in sarcoidosis. Curr. Opin. Pulm.Med., 2011, 17, 325–331 http://dx.doi.org/10.1097/MCP.0b013e3283480d36[WoS][Crossref]
• [26] Sharma S., Cardiac imaging in myocardial sarcoidosis and other cardiomyopathies. Curr. Opin. Pulm. Med., 2009, 15, 507–512 http://dx.doi.org/10.1097/MCP.0b013e32832ea4c7[Crossref][WoS]
• [27] Tadamura E., Yamamuro M., Kubo S., Kanao S., Saga T., Harada M., et al., Effectiveness of delayed enhanced MRI for identification of cardiac sarcoidosis: comparison with radionuclide imaging. A.J.R. Am. J. Roentgenol., 2005, 185, 110–115 [Crossref]
• [28] Penugonda N., Cardiac MRI in infiltrative disorders: a concise review. Curr. Cardiol. Rev., 2010, 6, 134–136 http://dx.doi.org/10.2174/157340310791162668[Crossref]
• [29] Vignaux O., Cardiac sarcoidosis: spectrum of MRI features. A.J.R. Am. J. Roentgenol., 2005, 184, 249–254 [Crossref]
• [30] Doughan A.R., Williams B.R., Cardiac sarcoidosis. Heart, 2006, 92, 282–288 http://dx.doi.org/10.1136/hrt.2005.080481[Crossref]
• [31] Smedema J.P., Truter R., de Klerk P.A., Zaaiman L., White L., Doubell A.F., Cardiac sarcoidosis evaluated with gadolinium-enhanced magnetic resonance and contrast-enhanced 64-slice computed tomography. Int. J. Cardiol., 2006, 112: 261–263 http://dx.doi.org/10.1016/j.ijcard.2005.07.059[Crossref]
• [32] Smedema J.P., Snoep G., Marinus P.G., van Kroonenburgh M.P., van Geuns R.J., Dassen W.R., et al., Evaluation of accuracy of gadolinium enhanced cardiovascular magnetic resonance imaging for diagnosis and evaluation of cardiac function in patients with cardiac sarcoidosis. J. Am. Coll. Cardiol. 2005, 45, 1683–1690 http://dx.doi.org/10.1016/j.jacc.2005.01.047[Crossref]
• [33] Ohira H., Tsujino I., Ishimaru S., Oyama N., Takei T., Tsukamoto E., et al., Myocardial imaging with 18F-Fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur. J. Nucl. Med. Mol. Imaging, 2008, 35, 933–941 http://dx.doi.org/10.1007/s00259-007-0650-8[Crossref]
• [34] Ichinose A., Otani H., Oikawa M., Takase K., Saito H., Shimokawa H., et al., MRI of cardiac sarcoidosis: basal and subepicardial localization of myocardial lesions and their effect on left ventricular function. A.J.R. Am. J. Roentgenol, 2008, 191, 862–869 http://dx.doi.org/10.2214/AJR.07.3089[Crossref][WoS]
• [35] Matoh F., Satoh H., Shiraki K., Odagiri K., Saitoh T., Urushida T., et al., The usefulness of delayed enhancement magnetic resonance imaging for diagnosis and evaluation of cardiac function in patients with cardiac sarcoidosis. J. Cardiol., 2008, 51, 179–188 http://dx.doi.org/10.1016/j.jjcc.2008.03.002[Crossref][WoS]
• [36] Stone M.E., Salter B., Fischer A., Perioperative management of patients with cardiac implantable electronic devices. Br J Anaesth. 2011, 107,Suppl 1: i16–26. http://dx.doi.org/10.1093/bja/aer354[WoS][Crossref]
• [37] Uemura A., Morimoto S., Hiramitsu S., Kato Y., Ito T., Hishida H., Histologic diagnostic rate of cardiac sarcoidosis: evaluation of endomyocardial biopsies. Am Heart J. 1999, 138, 299–302 http://dx.doi.org/10.1016/S0002-8703(99)70115-8[Crossref]
• [38] Schulte W., Kirsten D., Drent M., Costabel U., Cardiac involvement in sarcoidosis. Eur. Respir. J. Monogr., 2005, 10, 130–139 http://dx.doi.org/10.1183/1025448x.00032009[Crossref]
• [39] Sekiguchi M., Yazaki Y., Isobe M., Hiroe M., Cardiac sarcoidosis: diagnostic, prognostic, and therapeutic considerations. Cardiovasc. Drugs Ther., 1996, 10, 495–510 http://dx.doi.org/10.1007/BF00050989[Crossref]
• [40] Kim J.S, Judson M.A, Donnino R., Gold M., Cooper L.T Jr, Prystowsky E.N., et al. Cardiac sarcoidosis. Am. Heart J., 2009, 157, 9–21 http://dx.doi.org/10.1016/j.ahj.2008.09.009[Crossref]
• [41] Schutt A.C., Bullington W.M., Judson M.A., Pharmacotherapy for pulmonary sarcoidosis: a Delphi consensus study. Respir Med. 2010, 104, 717–723 http://dx.doi.org/10.1016/j.rmed.2009.12.009[Crossref]
• [42] Yazaki Y., Isobe M., Hiroe M., Morimoto S., Hiramitsu S., Nakano T., et al., Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am. J. Cardiol., 2001, 88, 1006–1010 http://dx.doi.org/10.1016/S0002-9149(01)01978-6[Crossref]
• [43] Londner C., Zendah I., Freynet O., Carton Z., Dion G., Nunes H., et al., Treatment of sarcoidosis. Rev. Med. Interne, 2011, 32, 109–113 http://dx.doi.org/10.1016/j.revmed.2010.10.351[Crossref][WoS]
• [44] Chapelon-Abric C., de Zuttere D., Duhaut P., Veyssier P., Wechsler B., Huong DL., et al., Cardiac sarcoidosis: a retrospective study of 41 cases. Medicine (Baltimore), 2004, 83, 315–334 http://dx.doi.org/10.1097/01.md.0000145367.17934.75[Crossref]
• [45] Roberts S.D., Wilkes D.S., Burgett R.A., Knox K.S., Refractory sarcoidosis responding to infliximab. Chest, 2003, 124, 2028–2031 http://dx.doi.org/10.1378/chest.124.5.2028[Crossref]
• [46] Deng J.C., Baughman R.P., Lynch J.P. III., Cardiac involvement in sarcoidosis. Semin. Respir. Crit. Care Med., 2002, 23, 513–527 http://dx.doi.org/10.1055/s-2002-36516[WoS][Crossref]
• [47] Baughman R.P., Costabel U., du Bois R.M., Treatment of sarcoidosis. Clin. Chest Med., 2008, 29, 533–548 http://dx.doi.org/10.1016/j.ccm.2008.03.012[Crossref][WoS]
• [48] Baughman R.P, Lower E.E, Drent M., Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them. Sarcoidosis Vasc. Diffuse Lung Dis., 2008, 2, 76–89
• [49] Greif M., Petrakopoulou P., Weiss M., Reithmann C., Reichart B., Nabauer M., et al., Cardiac sarcoidosis concealed by arrhythmogenic right ventricular dysplasia/cardiomyopathy. Nat. Clin. Pract. Cardiovasc. Med., 2008, 5, 231–236 http://dx.doi.org/10.1038/ncpcardio1146[Crossref]

Identifiers

DOI

10.2478/s11536-012-0095-8